InterCure Expects Positive EBITDA for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Adjusted EBITDA is expected to be positive in both the first and second halves of 2025, marking the Company's twelfth consecutive half-year of positive Adjusted EBITDA. Cash on hand of NIS 43M as of December 31, 2025. Alexander Rabinovich, CEO noted: "2025 marked a year of disciplined execution and renewed growth for InterCure. We delivered meaningful acceleration in the second half of the year with nearly 20% revenue growth and achieved our twelfth consecutive half-year of positive Adjusted EBITDA. The anticipated commencement of operations under the Botanico transaction and our strategic collaboration with Cannasoul are expected to further strengthen our pharmaceutical platform and global positioning. This marks another key milestone with our first significant revenues in the German market, as we expect continued execution of our global expansion strategy in Germany and additional markets throughout 2026. As regulatory frameworks continue to evolve, particularly in the United States and Europe, we believe InterCure is strategically positioned to leverage its vertically integrated model, scientific leadership, and international partnerships to drive long-term value for patients and shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCR
About INCR
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InterCure Secures NIS 22 Million Funding for Growth
- Funding Scale and Purpose: InterCure has secured NIS 22 million (approximately $7.4 million) through a private placement aimed at supporting the company's recovery, expanding production capacity, and pursuing growth opportunities in regulated medical cannabis markets like Israel and Germany.
- Investor Background: The financing includes commitments from key shareholders, such as CEO Alexander Rabinovich, along with prominent pharma-focused hedge funds like Bennu Pharma Fund Ltd., indicating strong market confidence in the company.
- Equity Issuance and Warrants: InterCure will issue 7,895,143 ordinary shares at NIS 2.75 (approximately $0.94) and provide warrants allowing investors to purchase additional shares at NIS 4.125 (approximately $1.41), representing a 53% premium to the reference price.
- Strategic Significance and Market Reaction: Rabinovich stated that this financing marks a crucial step in the company's recovery and growth strategy, expected to support the expansion of the Nir Oz facility to meet rising demand in Israel and international markets while accelerating global expansion efforts, particularly in Germany.
See More
InterCure Signs Binding Term Sheet for Private Placement
- Financing Size: InterCure's binding term sheet for private placement initially raises NIS 22 million (approximately $7.4 million), with potential total proceeds reaching NIS 54 million (approximately $18.6 million), indicating strong market appeal.
- Investor Support: The financing is backed by both existing and new investors, including CEO Alexander Rabinovich and Bennu Pharma Fund, reflecting management's confidence in the company's future growth prospects.
- Share Issuance: InterCure will issue approximately 7.9 million ordinary shares at NIS 2.75 per share, with investors also receiving warrants to purchase an additional 7.9 million shares at NIS 4.125 per share, representing a roughly 53% premium to the reference closing price.
- Financing Potential: Should all warrants be exercised for cash, total proceeds from the financing could increase to approximately NIS 54 million, with warrants remaining exercisable for five years, enhancing the company's future financial flexibility.
See More
InterCure Completes First Tranche of Botanico Acquisition Expanding U.S. Market Access
- Transaction Completion: InterCure has successfully completed the first tranche of its acquisition of Botanico, gaining exclusive access to U.S. genetics and advanced AI technologies, which is expected to significantly enhance its competitiveness in the international medical cannabis market.
- Market Expansion: This acquisition provides InterCure with a collection of award-winning U.S. cannabis genetics and brands, further solidifying its growth momentum in the German market while laying the groundwork for future expansion in the U.S.
- Equity Issuance: As part of the transaction, InterCure will issue 2,471,061 ordinary shares and an additional 2,470,073 shares upon satisfaction of the agreement conditions, strengthening its capital structure to support future growth.
- Strategic Evaluation: InterCure is evaluating opportunities in the regulated U.S. medical cannabis market, with the CEO stating that the acquisition aligns with growth in the German market and changes in the U.S. regulatory landscape, supporting the company's vision of becoming a leading international medical cannabis enterprise.
See More
InterCure Reports Significant FY Revenue Growth
- Strong Financial Performance: InterCure's fiscal year revenue reached NIS 270.2 million, reflecting significant growth compared to the previous year, indicating the company's robust market performance and business expansion capabilities.
- Adjusted EBITDA Surge: The adjusted EBITDA of NIS 47 million represents a more than 90% increase from NIS 24 million in 2024, accounting for 17% of total revenue, showcasing the company's enhanced profitability.
- Reduced Net Loss: The company reported a net loss of NIS 37 million, a substantial decrease from NIS 73 million in 2024, primarily reflecting non-cash provisions related to Bazalet debt and the impact of the ongoing war.
- Nasdaq Notification: InterCure received a notification from Nasdaq regarding minimum bid requirements, indicating challenges faced in the capital markets, necessitating measures to ensure compliance and maintain investor confidence.
See More
InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA
- Significant Revenue Growth: InterCure reported over NIS 270 million in revenue for 2025, a 13% increase year-over-year, with NIS 140 million in the second half, reflecting a 24% growth compared to the same period in 2024, indicating strong market recovery.
- Consistent Positive Adjusted EBITDA: The company achieved an Adjusted EBITDA of NIS 47 million in 2025, over 90% higher than 2024, representing 17% of revenue, marking the twelfth consecutive half-year of positive Adjusted EBITDA, showcasing sustained profitability.
- Positive Operating Cash Flow: InterCure generated NIS 17 million in positive operating cash flow in 2025, a significant turnaround from a negative cash flow of NIS 67 million in 2024, demonstrating substantial progress in resuming production and sales.
- Strategic Acquisitions and Partnerships: The company entered into a strategic investment agreement with Cannasoul R&D Ltd., acquiring a 28% stake with plans to increase to 51% within two years, enhancing its research capabilities and supporting its positioning in the U.S. market.
See More
InterCure Receives Noncompliance Notice from Nasdaq
- Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
- Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
- Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
- Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.
See More
InterCure Secures NIS 22 Million Funding for Growth
- Funding Scale and Purpose: InterCure has secured NIS 22 million (approximately $7.4 million) through a private placement aimed at supporting the company's recovery, expanding production capacity, and pursuing growth opportunities in regulated medical cannabis markets like Israel and Germany.
- Investor Background: The financing includes commitments from key shareholders, such as CEO Alexander Rabinovich, along with prominent pharma-focused hedge funds like Bennu Pharma Fund Ltd., indicating strong market confidence in the company.
- Equity Issuance and Warrants: InterCure will issue 7,895,143 ordinary shares at NIS 2.75 (approximately $0.94) and provide warrants allowing investors to purchase additional shares at NIS 4.125 (approximately $1.41), representing a 53% premium to the reference price.
- Strategic Significance and Market Reaction: Rabinovich stated that this financing marks a crucial step in the company's recovery and growth strategy, expected to support the expansion of the Nir Oz facility to meet rising demand in Israel and international markets while accelerating global expansion efforts, particularly in Germany.
See More
InterCure Signs Binding Term Sheet for Private Placement
- Financing Size: InterCure's binding term sheet for private placement initially raises NIS 22 million (approximately $7.4 million), with potential total proceeds reaching NIS 54 million (approximately $18.6 million), indicating strong market appeal.
- Investor Support: The financing is backed by both existing and new investors, including CEO Alexander Rabinovich and Bennu Pharma Fund, reflecting management's confidence in the company's future growth prospects.
- Share Issuance: InterCure will issue approximately 7.9 million ordinary shares at NIS 2.75 per share, with investors also receiving warrants to purchase an additional 7.9 million shares at NIS 4.125 per share, representing a roughly 53% premium to the reference closing price.
- Financing Potential: Should all warrants be exercised for cash, total proceeds from the financing could increase to approximately NIS 54 million, with warrants remaining exercisable for five years, enhancing the company's future financial flexibility.
See More
InterCure Completes First Tranche of Botanico Acquisition Expanding U.S. Market Access
- Transaction Completion: InterCure has successfully completed the first tranche of its acquisition of Botanico, gaining exclusive access to U.S. genetics and advanced AI technologies, which is expected to significantly enhance its competitiveness in the international medical cannabis market.
- Market Expansion: This acquisition provides InterCure with a collection of award-winning U.S. cannabis genetics and brands, further solidifying its growth momentum in the German market while laying the groundwork for future expansion in the U.S.
- Equity Issuance: As part of the transaction, InterCure will issue 2,471,061 ordinary shares and an additional 2,470,073 shares upon satisfaction of the agreement conditions, strengthening its capital structure to support future growth.
- Strategic Evaluation: InterCure is evaluating opportunities in the regulated U.S. medical cannabis market, with the CEO stating that the acquisition aligns with growth in the German market and changes in the U.S. regulatory landscape, supporting the company's vision of becoming a leading international medical cannabis enterprise.
See More
InterCure Reports Significant FY Revenue Growth
- Strong Financial Performance: InterCure's fiscal year revenue reached NIS 270.2 million, reflecting significant growth compared to the previous year, indicating the company's robust market performance and business expansion capabilities.
- Adjusted EBITDA Surge: The adjusted EBITDA of NIS 47 million represents a more than 90% increase from NIS 24 million in 2024, accounting for 17% of total revenue, showcasing the company's enhanced profitability.
- Reduced Net Loss: The company reported a net loss of NIS 37 million, a substantial decrease from NIS 73 million in 2024, primarily reflecting non-cash provisions related to Bazalet debt and the impact of the ongoing war.
- Nasdaq Notification: InterCure received a notification from Nasdaq regarding minimum bid requirements, indicating challenges faced in the capital markets, necessitating measures to ensure compliance and maintain investor confidence.
See More
InterCure Reports Strong 2025 Financial Results with Positive Adjusted EBITDA
- Significant Revenue Growth: InterCure reported over NIS 270 million in revenue for 2025, a 13% increase year-over-year, with NIS 140 million in the second half, reflecting a 24% growth compared to the same period in 2024, indicating strong market recovery.
- Consistent Positive Adjusted EBITDA: The company achieved an Adjusted EBITDA of NIS 47 million in 2025, over 90% higher than 2024, representing 17% of revenue, marking the twelfth consecutive half-year of positive Adjusted EBITDA, showcasing sustained profitability.
- Positive Operating Cash Flow: InterCure generated NIS 17 million in positive operating cash flow in 2025, a significant turnaround from a negative cash flow of NIS 67 million in 2024, demonstrating substantial progress in resuming production and sales.
- Strategic Acquisitions and Partnerships: The company entered into a strategic investment agreement with Cannasoul R&D Ltd., acquiring a 28% stake with plans to increase to 51% within two years, enhancing its research capabilities and supporting its positioning in the U.S. market.
See More
InterCure Receives Noncompliance Notice from Nasdaq
- Noncompliance Notice: InterCure received a noncompliance notice from Nasdaq last week, indicating that the company has failed to meet certain listing requirements, which could impact stock trading stability and investor confidence.
- Potential Consequences: This notice may expose the company to the risk of delisting, affecting its ability to raise funds and its market reputation, especially as investor scrutiny on compliance increases in the current market environment.
- Response Measures: InterCure must implement effective measures to address the noncompliance issues, including potential financial restructuring or improving corporate governance to ensure adherence to Nasdaq's listing standards.
- Market Reaction: Investor reactions to this news may lead to stock price volatility, with potential selling pressure in the short term, thereby impacting the company's market capitalization and future financing plans.
See More
